Using similar logic, Koski, Czerniecki, and their collaborators demonstrated that HER-2/neu-loaded DC1 cells injected into the draining lymph node were effective as neoadjuvant therapy for breast cancer [7, 27]. This evidence concerns the gene ERBB2 and breast cancer.